<DOC>
	<DOCNO>NCT01375842</DOCNO>
	<brief_summary>This Phase I , multicenter , first human , open-label , dose escalation study evaluate safety , tolerability , pharmacokinetics atezolizumab ( MPDL3280A ) administer single agent intravenous ( IV ) infusion every three week ( q3w ) participant locally advance metastatic solid malignancy hematologic malignancy . The study conduct two cohort : Dose-escalation cohort Expansion cohort .</brief_summary>
	<brief_title>A Phase 1 Study Atezolizumab ( Engineered Anti-Programmed Death-Ligand 1 PDL1 Antibody ) Evaluate Safety , Tolerability Pharmacokinetics Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age great equal [ &gt; /= ] 18 year , participant 16 17 year old would enrol consultation Medical Monitor Histologically cytologically document , incurable metastatic solid tumor hematologic malignancy advance ( nonresectable ) recurrent progress since last antitumor therapy recognize standard curative therapy exist Representative tumor specimens paraffin block ( prefer ) least 15 unstained slide , associate pathology report Adequate hematologic end organ function Measurable disease per RECIST v1.1 participant solid malignancy . Diseasespecific criteria participant prostate cancer , glioblastoma multiforme ( GBM ) , malignant lymphoma , multiple myeloma For woman childbearing potential : agreement remain abstinent use contraceptive method Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 For participant undergo serial biopsy doseescalation cohort , baseline tumor tissue sample core needle biopsy deep tumor tissue organs excisional punch biopsy cutaneous subcutaneous lesion ( &gt; /=5 millimeter [ mm ] diameter amenable serial biopsy ) Known primary central nervous system ( CNS ) malignancy symptomatic CNS metastasis Known hypersensitivity pharmaceutical produce Chinese hamster ovary cell component atezolizumab formulation History risk autoimmune disease ( example , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , Bell 's palsy , GuillainBarré syndrome , multiple sclerosis , autoimmune thyroid disease , vasculitis ) History human immunodeficiency virus ( HIV ) infection , active hepatitis B ( chronic acute ) , hepatitis C infection Signs symptom infection within 2 week prior Cycle 1 , Day 1 Malignancies disease study within 5 year prior Cycle 1 , Day 1 Participants prior allogeneic bone marrow transplantation prior solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PD-L1</keyword>
	<keyword>PD-1</keyword>
	<keyword>lymphoma</keyword>
	<keyword>esophageal cancer</keyword>
	<keyword>antiPD-L1</keyword>
	<keyword>MPDL3280A</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Renal cell Carcinoma ( RCC )</keyword>
	<keyword>Melanoma ( MEL )</keyword>
	<keyword>Non-small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Heme Malignancies</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>MPDL320A</keyword>
</DOC>